Literature DB >> 31911262

Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.

Dipal M Patel1, Heather Thiessen-Philbrook2, Jeremiah R Brown3, Eric McArthur4, Dennis G Moledina5, Sherry G Mansour5, Michael G Shlipak6, Jay L Koyner7, Peter Kavsak8, Richard P Whitlock9, Allen D Everett10, David J Malenka3, Amit X Garg11, Steven G Coca12, Chirag R Parikh13.   

Abstract

BACKGROUND: Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant post-operative morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 (gal-3) are biomarkers of myocardial remodeling and fibrosis; however, their potential association with post-operative changes is unknown.
METHODS: We measured peri-operative plasma sST2 and gal-3 levels in two prospective cohorts (TRIBE-AKI and NNE) of over 1800 patients who underwent cardiac surgery. sST2 and gal-3 levels were evaluated for association with a composite primary outcome of cardiovascular event or mortality over median follow-up periods of 3.4 and 6.0 years, respectively, for the two cohorts. Meta-analysis of hazard ratio estimates from the cohorts was performed using random effects models.
RESULTS: Cohorts demonstrated event rates of 70.2 and 66.8 per 1000 person-years for the primary composite outcome. After adjustment for clinical covariates, higher post-operative sST2 and gal-3 levels were significantly associated with cardiovascular event or mortality [pooled estimate HRs: sST2 1.29 (95% CI 1.16, 1.44); gal-3 1.26 (95% CI 1.09, 1.46)]. These associations were not significantly modified by pre-operative congestive heart failure or AKI.
CONCLUSIONS: Higher post-operative sST2 and gal-3 values were associated with increased incidence of cardiovascular event or mortality. These two biomarkers should be further studied for potential clinical utility for patients undergoing cardiac surgery. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31911262      PMCID: PMC7008086          DOI: 10.1016/j.ahj.2019.11.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  58 in total

1.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

Authors:  W H Wilson Tang; Kevin Shrestha; Zhili Shao; Allen G Borowski; Richard W Troughton; James D Thomas; Allan L Klein
Journal:  Am J Cardiol       Date:  2011-05-19       Impact factor: 2.778

Review 2.  Perioperative cardiac biomarkers: the utility and timing.

Authors:  William Scott Beattie; Duminda N Wijeysundera
Journal:  Curr Opin Crit Care       Date:  2013-08       Impact factor: 3.687

Review 3.  The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2.

Authors:  Thomas Mueller; Benjamin Dieplinger
Journal:  Expert Rev Mol Diagn       Date:  2013-01       Impact factor: 5.225

4.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

Authors:  Yun-He Liu; Martin D'Ambrosio; Tang-dong Liao; Hongmei Peng; Nour-Eddine Rhaleb; Umesh Sharma; Sabine André; Hans-J Gabius; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-19       Impact factor: 4.733

5.  Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND.

Authors:  A Rogier van der Velde; Wouter C Meijers; Edwin R van den Heuvel; Stephan J Bakker; Wiek H van Gilst; Pim van der Harst; Hans Hillege; Rudolf A de Boer
Journal:  Int J Cardiol       Date:  2016-07-31       Impact factor: 4.164

Review 6.  Clinical relevance of sST2 in cardiac diseases.

Authors:  Domingo A Pascual-Figal; Antonio Lax; Maria Teresa Perez-Martinez; Maria del Carmen Asensio-Lopez; Jesus Sanchez-Mas
Journal:  Clin Chem Lab Med       Date:  2016-01       Impact factor: 3.694

7.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

Authors:  Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

8.  Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma.

Authors:  Ying Lei; Vamsi Boinapally; Anna Zoltowska; Mikael Adner; Lars Hellman; Gunnar Nilsson
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

9.  Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.

Authors:  Cho-Kai Wu; Mao-Yuan Su; Jen-Kuang Lee; Fu-Tien Chiang; Juey-Jen Hwang; Jiunn-Lee Lin; Jin-Jer Chen; Fu-Tong Liu; Chia-Ti Tsai
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

10.  Soluble ST2 and Galectin-3: What We Know and Don't Know Analytically.

Authors:  Thomas Mueller; Benjamin Dieplinger
Journal:  EJIFCC       Date:  2016-08-01
View more
  3 in total

1.  Urine Alpha-1-Microglobulin Levels and Acute Kidney Injury, Mortality, and Cardiovascular Events following Cardiac Surgery.

Authors:  Jonathan G Amatruda; Michelle M Estrella; Amit X Garg; Heather Thiessen-Philbrook; Eric McArthur; Steven G Coca; Chirag R Parikh; Michael G Shlipak
Journal:  Am J Nephrol       Date:  2021-09-02       Impact factor: 3.754

Review 2.  Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill.

Authors:  Jianli Bi; Vidu Garg; Andrew R Yates
Journal:  Biomolecules       Date:  2021-01-27

3.  Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission.

Authors:  L Boutin; M Legrand; M Sadoune; A Mebazaa; E Gayat; C E Chadjichristos; F Dépret
Journal:  Crit Care       Date:  2022-01-06       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.